FACULTY

Carolyn S.P. Lam, MBBS, PhD, FRCP National Heart Centre Singapore Singapore

Hooman Kamel, MD Weill Cornell Medicine New York, NY

Video 1: The Evolving Anticoagulation Landscape

• The evolving antithrombotic/anticoagulant treatment landscape in AFib and how it has transformed over the past few decades
• Key unmet needs that persist across thromboembolism despite advances in anticoagulation therapy
• Why many patients with AFib remain undertreated for stroke prevention, and the implications of a patient not receiving treatment
• The continued burden of stroke and thrombosis despite decades of progress
• How real and perceived bleeding risk can limit anticoagulant use and adherence

Video 2: Scientific Innovation and Emerging Approaches

• Why FXI/FXIa is an attractive therapeutic target for potentially reducing risk of thromboembolic events due to AFib
• How FXI/FXIa inhibition may address some of the challenges in stroke prevention in patients with AFib, particularly the balance between thrombosis prevention and bleeding risk
• The biological rationale for targeting FXI/FXIa, including the potential to preserve physiologic hemostasis while reducing pathologic thrombosis
• Emerging evidence, including genetic data and Phase 2/Phase 3 findings, supporting the potential of FXI/FXIa inhibition
• Potential implications for treatment strategies in high-risk patients, including those with prior bleeding, comorbidities or concurrent therapies

Video 3: Clinical Decision-Making and Treatment Challenges

• How clinicians weigh the benefit-risk profile of anticoagulants in practice
• How to address complacency with anticoagulant therapy in AFib and hesitancy due to potential bleeding concerns
• The role of patient education and trust in supporting adherence
• Real-world complexities, including comorbidities and concurrent therapies
• The importance of coordination across specialties in patient management

Video 4: Looking Ahead – Future Considerations

• Key real-world considerations if therapies that inhibit FXI/FXIa become available as a treatment option
• The importance of trial populations that reflect real-world patients to support applicability and adoption
• The need for strong clinical outcomes data demonstrating efficacy, safety and reduced bleeding risk
• Practical considerations for adoption, including physician confidence and management in real-world clinical settings